Comparison · NCT00047879-sae
Glioblastoma Multiforme Stratum vs Anaplastic Glioma Stratum: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Glioblastoma Multiforme Stratum vs Anaplastic Glioma Stratum: serious adverse events. Trial comparisons, record NCT00047879-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00047879-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.75 | 0.301 | 0.954 | wilson | |
| Risk in group 2 | 0.667 | 0.208 | 0.939 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0833 | -0.442 | 0.586 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.13 | 0.422 | 3 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.0554 | 40.6 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Glioblastoma Multiforme Stratum than on Anaplastic Glioma Stratum | 12 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Glioblastoma Multiforme Stratum | Glioblastoma multiforme is one of the most common and aggressive types of brain tumor. | 3 | 4 | EG000 |
| Group 2 | Anaplastic Glioma Stratum | Anaplastic glioma is a type of brain tumor that develops from star-shaped glial cells that support nerve cells. Anaplastic oligodendroglioma is a malignant type of brain tumor sensitive to treatment with chemotherapy and radiotherapy. | 2 | 3 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 4 months
Source ClinicalTrials.gov
Trial
- Title
- Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
- NCT number
- NCT00047879
- Phases
- PHASE2
- Conditions
- Glioma
- Interventions
- PEG-interferon alfa-2b, Thalidomide
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2011-10-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00047879?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00047879-sae